Aidoc
Last updated: May 1, 2026
Israeli clinical AI platform company providing real-time medical imaging triage, workflow prioritization, and decision-support integration for acute care settings at scale across 1,600+ hospitals globally.
Visit WebsiteCompany Overview
Aidoc is a clinical AI platform company founded in 2016 in Tel Aviv that has built a proprietary enterprise system (aiOS™) for integrating algorithmic decision support directly into hospital imaging and clinical workflows. The core technology addresses a fundamental bottleneck in time-sensitive medical care: the lag between image acquisition (CT, MRI, X-ray) and radiologist review, and between radiologist findings and clinical action. Aidoc's algorithms flag critical and incidental findings, prioritize worklists, and alert care teams in real time, reducing time-to-intervention in conditions such as acute stroke, pulmonary embolism, pneumothorax, and intracranial hemorrhage—cases where minutes can determine clinical outcome.
The company operates as a healthcare infrastructure play rather than a pure software vendor. Aidoc integrates into existing hospital PACS, EHR, and communication systems, supporting both third-party algorithms and proprietary neural networks. Its stated deployment footprint is 1,600+ medical centers across multiple health systems and geographies, with customer concentration in North America and broader international presence. The company is venture-backed, having raised multiple funding rounds including Series D, indicating institutional confidence and substantial capital deployment. The commercial model targets large hospital networks and integrated delivery systems where imaging throughput and clinical responsiveness directly affect revenue, liability, and reputation.
From a technology standpoint, Aidoc's competitive position rests on workflow integration depth and clinical outcome evidence, rather than on single-algorithm performance. Real-time notification systems, care pathway orchestration, and persistent measurement of triage impact differentiate it from narrow point-of-care AI applications. The company positions itself around a "CARE" framework—an abstraction for building clinical AI workflows—and maintains partnerships with other AI developers, creating a platform ecosystem.
Defense-adjacent relevance is substantive and credible. Military and humanitarian medical operations (field hospitals, disaster response, casualty management) face identical constraints: massive imaging/patient volume, time-criticality, distributed care environments, and limited radiologist availability. Rapid, AI-enabled triage in austere settings would improve both battlefield casualty survival and humanitarian response capacity. Israel's defense-oriented tech ecosystem and Aidoc's origins suggest familiarity with these use cases, though no public evidence of defense contracts exists. The dual-use relevance is not forced—it follows naturally from the problem the company solves.
The company faces typical healthcare AI risks: long procurement cycles, stringent clinical validation demands, reimbursement uncertainty, and competitive pressure from imaging vendors (GE, Philips, Siemens) who are integrating AI into their own platforms. Regulatory pathways (FDA 510(k), Class II clearance) appear to be navigated with maturity, though evidence of sustained outcome publication and health economic validation remains material to market expansion.
Dual-Use Assessment
Aidoc's imaging triage, real-time alerting, and workflow orchestration capabilities are substantively dual-use. Civilian acute care workflows in hospitals are directly analogous to military and humanitarian medical operations, disaster response, and combat casualty management. Field hospitals, distributed care systems, and personnel-limited medical environments face identical time-criticality and throughput constraints. No public defense contracts are known, but the technology would credibly enhance medical response speed and decision quality in austere and high-volume casualty scenarios.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Aidoc has credible technology moats through workflow integration depth, established customer base across 1,600+ hospitals, private venture financing trajectory through Series D, sustained market demand in high-stakes acute care, and substantive dual-use adjacency. The company is mature enough to show clinical traction yet positioned in a high-margin, defensible healthcare AI segment with expanding adoption. Defense-adjacent relevance is genuine—not contrived—and the company's Israeli origins suggest strategic familiarity with resilience and security-critical applications.
Strategic Value to U.S.-Israel Alliance
Clinical decision speed and accuracy directly correlate with patient outcomes and hospital risk mitigation. Aidoc's platform improves both at scale, reduces radiologist cognitive load, and operates in a domain where competitors are encumbered by legacy incumbent dynamics. The same capabilities that improve civilian care response directly enhance military medical readiness, emergency management, and austere-environment medical response.
Key Technologies
- Deep learning-based medical image analysis and finding prioritization
- Real-time integration into hospital PACS and EHR systems
- Workflow orchestration and care-team alerting infrastructure (aiOS platform)
- Incidental finding detection and capture systems
- Outcome measurement and triage performance analytics
Use Cases & Applications
- Acute stroke detection and time-to-intervention reduction
- Pulmonary embolism rapid triage and alert
- Pneumothorax and critical finding notification
- Intracranial hemorrhage and neurological emergency prioritization
- Imaging worklist prioritization in high-volume radiology departments
- Incidental finding capture to prevent missed diagnoses
- Distributed and austere medical operations triage (defense-adjacent)
- Casualty management in humanitarian and disaster response contexts
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Official website Primary public reference for company identity, positioning, and current web presence.
- Profile update timestamp Last updated in the Claw & Talon database on May 1, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Aidoc may matter as a Defense & National Security entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Aidoc's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What export-control, supply-chain, manufacturing, or classified-market constraints could affect U.S. and allied adoption?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Defense & National Security sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.